Bioventus Inc. last reported quarterly results on Nov 2, 2026, for Q3 FY2026 (the quarter ended Sep 26, 2026): revenue of $142.4 million (+2.7% year over year) and diluted EPS of $0.08. It usually reports 37–64 days after a quarter ends. Based on that pattern, the next release is estimated for around Mar 4, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Mar 5, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 37–64 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 2, 2026
37 days after quarter end
|
Q3 FY2026
ended Sep 26, 2026
|
142
+2.7%
|
6
+89.8%
|
0.08
+60.0%
|
|
Aug 5, 2026
39 days after quarter end
|
Q2 FY2026
ended Jun 27, 2026
|
153
+3.8%
|
33
+348.3%
|
0.47
+327.3%
|
|
May 6, 2026
39 days after quarter end
|
Q1 FY2026
ended Mar 28, 2026
|
132
+6.6%
|
3
+218.1%
|
0.04
+200.0%
|
|
Mar 5, 2026
64 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
158
+2.8%
|
15
+3902.8%
|
0.21
+3693.4%
|
|
Nov 4, 2025
38 days after quarter end
|
Q3 FY2025
ended Sep 27, 2025
|
139
-0.2%
|
3
+161.1%
|
0.05
+162.5%
|
|
Aug 6, 2025
39 days after quarter end
|
Q2 FY2025
ended Jun 28, 2025
|
148
-2.4%
|
7
+129.0%
|
0.11
+127.5%
|
|
May 6, 2025
38 days after quarter end
|
Q1 FY2025
ended Mar 29, 2025
|
124
-4.3%
|
-3
+46.1%
|
-0.04
+50.0%
|
|
Mar 11, 2025
70 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
154
+13.5%
|
-0
+93.6%
|
-0.01
+93.9%
|
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- BVS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Durham, NC
- SEC filer status
- Accelerated filer, Emerging growth company
- SEC CIK
- 1665988
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.